Last reviewed · How we verify
A Randomized, Open-label, Parallel Group, Multi-center Phase II Clinical Trial Evaluating Effect of Addition of DCVAC/OvCa to Standard Chemotherapy in Women With Relapsed Platinum (Pt)-Resistant Epithelial Ovarian Carcinoma
The purpose of this study is to determine whether DCVAC/OvCa added to chemotherapy may result in prolongation of Overall Survival (OS).
Details
| Lead sponsor | SOTIO a.s. |
|---|---|
| Phase | Phase 2 |
| Status | TERMINATED |
| Enrolment | 22 |
| Start date | 2014-01 |
| Completion | 2016-08 |
Conditions
- Epithelial Ovarian Carcinoma
Interventions
- DCVAC/OvCa
- Standard of Care (Paclitaxel or topotecan or doxorubicin)
Primary outcomes
- Overall survival (all cause mortality) — 72 weeks
Countries
Czechia, Germany, Poland